Format

Send to

Choose Destination
Onco Targets Ther. 2014 Jun 18;7:1111-4. doi: 10.2147/OTT.S64706. eCollection 2014.

Recall radiation dermatitis by sorafenib following stereotactic body radiation therapy.

Author information

1
Division of Radiation Oncology, Department of Radiology, New Taipei City, Taiwan ; Department of Medicine, National Yang-Ming University, Taipei, Taiwan ; Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
2
Division of Medical Oncology and Hematology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
3
Division of Radiation Oncology, Department of Radiology, New Taipei City, Taiwan ; Department of Radiation Oncology, National Defense Medical Center, Taipei, Taiwan ; Oriental Institute of Technology, New Taipei City, Taiwan.
4
Division of Radiation Oncology, Department of Radiology, New Taipei City, Taiwan.

Abstract

We report on a 63-year-old man with a history of hepatitis B virus-related hepatocellular carcinoma with a thrombus extending into the inferior vena cava, who received image-guided stereotactic body radiation therapy (SBRT) with helical tomotherapy, followed by sorafenib. A total tumor dose of 48 Gy was delivered by 6 fractions within 2 weeks. The tumor responded dramatically, and the patient tolerated the courses well. Ten days after SBRT, sorafenib (200 mg), at 1.5 tablets twice a day, was prescribed. One week later, grade 2 recall radiation dermatitis subsequently developed in the previous SBRT off-target area. SBRT followed by sorafenib for the treatment of a portal vein thrombosis provided effective results, but the potential risk of enhanced adverse effects between radiation and sorafenib should be considered with caution, especially under a SBRT scheme.

KEYWORDS:

hepatocellular carcinoma; recall radiation dermatitis

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center